Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel vs Abiraterone or Enzalutamide in Poor Prognosis mCRPC
NCT02254785Phase 2Unknown
- Sponsor
- BC Cancer
- Start
- Oct 2014
- Primary completion
- May 2020
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of cabazitaxel ginsenoside liposome injection in metastatic castration-resistant prostate cancer (mCRPC), sponsored by BC Cancer. Status: unknown.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02254785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254785.